Abstract
Blinatumomab is a member of a novel class of T cell-engaging bispecific antibodies, so-called Bispecific T cell Engager (BiTEs). It is directed against the B cell differentiation antigen CD19 and intended for treatment of B cell malignancies. In clinical phase I/II trials, blinatumomab showed remarkable single-agent activity in patients with relapsed and/or refractory (R/R) non-Hodgkin lymphoma and R/R B cell precursor acute lymphoblastic leukemia (B-precursor ALL). Cytokine release syndrome and neurological side effects were dose-limiting. Adverse effects were well manageable and transient in nature. Based on results of an international phase II trial, blinatumomab received FDA approval for the treatment of R/R B-precursor ALL in December 2014. Ongoing and future trials will contribute to further optimization of blinatumomab-based T cell therapy and have to show that integration of blinatumomab in current and innovative treatment protocols improves overall survival and quality of life of patients with B cell malignancies.
Keywords:
B-precursor ALL; BiTE®; NHL; blinatumomab; immunotherapy.
MeSH terms
-
Animals
-
Antibodies, Bispecific / economics
-
Antibodies, Bispecific / pharmacology
-
Antibodies, Bispecific / therapeutic use*
-
Antigens, CD19 / metabolism
-
Antineoplastic Agents / economics
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
CD3 Complex / metabolism
-
Clinical Trials as Topic
-
Cost-Benefit Analysis
-
Drug Evaluation, Preclinical
-
Drug Resistance, Neoplasm
-
Humans
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / immunology
-
Lymphoma, Non-Hodgkin / metabolism
-
Lymphoma, Non-Hodgkin / pathology
-
Molecular Targeted Therapy
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Neoplasms / metabolism*
-
Neoplasms / pathology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
-
Recurrence
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
-
T-Lymphocytes / metabolism
-
Treatment Outcome
Substances
-
Antibodies, Bispecific
-
Antigens, CD19
-
Antineoplastic Agents
-
CD3 Complex
-
blinatumomab